Rheumatoid arthritis and cardiovascular diseases: close relatives or friends?

The problem of comorbidity is widely discussed in modern medical literature. Its role in rheumatic diseases is of particular interest due to their multifactorial nature and the involvement of a wide range of pathogenetic mechanisms. For many years, researchers around the world have noted correlations between the presence of active autoimmune disorders and the complicated course of cardiovascular diseases. A deeper understanding of the pathogenetic mechanisms at the present stage of development of rheumatology allows us to take a fresh look at the relationship between atherosclerosis and rheumatoid arthritis. The definition of multimorbidity developed in recent years and the results of recent scientific studies may contribute to a more correct choice of tactics for managing patients with a combination of these two diseases.

[1]  I. Bruce,et al.  EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome , 2022, Annals of the Rheumatic Diseases.

[2]  E. Nasonov,et al.  Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis. , 2021, Kardiologiia.

[3]  C. Inderjeeth,et al.  The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review , 2020, Rheumatology International.

[4]  G. Collins,et al.  Prevalence, Deaths, and Disability‐Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990–2017 , 2020, Arthritis & rheumatology.

[5]  Е. А. Галушко,et al.  Кардиоренальный синдром у больных ревматоидным артритом , 2019 .

[6]  G. Collins,et al.  Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017 , 2019, Annals of the rheumatic diseases.

[7]  E. Fedorov,et al.  Development of the doctrine of auto-inflammatory diseases in the XXI century , 2019, Rheumatology Science and Practice.

[8]  Т. В. Попкова,et al.  Функциональные нарушения макрофагов при ревматоидном артрите и атеросклерозе , 2018 .

[9]  A. Syvänen,et al.  Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis , 2018, Annals of the rheumatic diseases.

[10]  Римма Михайловна Балабанова,et al.  Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015–2016 гг. , 2018 .

[11]  J. Askling,et al.  Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact? , 2017, Annals of the rheumatic diseases.

[12]  Е. Л. Насонов,et al.  Противовоспалительная терапия атеросклероза – вклад и уроки ревматологии , 2017 .

[13]  J. Primdahl,et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.

[14]  Д. Ш. Вайсман,et al.  Анализ смертности от болезней костно-мышечной системы по первоначальной и множественным причинам у жителей Тульской области , 2017 .

[15]  Евгений Львович Насонов,et al.  Факторы риска развития стеноза коронарных артерий у больных ревматоидным артритом , 2017 .

[16]  H. Boshuizen,et al.  Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study , 2016, Rheumatology International.

[17]  Евгений Львович Насонов,et al.  Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные , 2016, RSP 2016.

[18]  Е. Л. Насонов,et al.  Роль интерлейкина 1 в развитии заболеваний человека , 2016, RSP 2016.

[19]  Евгений Львович Насонов.  Метотрексат при ревматоидном артрите - 2015: новые факты и идеи , 2015 .

[20]  A. Barton,et al.  Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register , 2015, Annals of the rheumatic diseases.

[21]  C. Bombardier,et al.  Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada , 2015, Arthritis care & research.

[22]  E. Nasonov,et al.  [Left and right ventricular diastolic dysfunction in patients with early rheumatoid arthritis before prescribing disease-modifying antirheumatic therapy]. , 2015, Terapevticheskii arkhiv.

[23]  E. Nasonov,et al.  Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. , 2015, Current medicinal chemistry.

[24]  Евгений Львович Насонов,et al.  Кардиоваскулярный риск у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии (предварительные данные исследования РЕМАРКА) , 2014, RSP 2014.

[25]  G. Firestein.  The disease formerly known as rheumatoid arthritis , 2014, Arthritis Research & Therapy.

[26]  Javier Martín,et al.  Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[27]  Евгений Львович Насонов,et al.  Метаболический синдром при ревматоидном артрите , 2013, RSP 2013.

[28]  T. Nieminen,et al.  How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? , 2012, Annals of the rheumatic diseases.

[29]  A. Gerasimov,et al.  THE RELATIONSHIP OF CARDIOVASCULAR RISK FACTORS AND ARTERIAL WALL STIFFNESS IN WOMEN WITH A HIGH ACTIVITY OF RHEUMATOID ARTHRITIS , 2012 .

[30]  J. Gómez-Reino,et al.  Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study , 2011, BMC musculoskeletal disorders.

[31]  J. Norris,et al.  The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. , 2010, Arthritis and rheumatism.

[32]  P. Kovanen,et al.  Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation , 2010, PloS one.

[33]  K. Moore,et al.  NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease , 2010, Nature.

[34]  Array Львович Насонов,et al.  Определение кальция в коронарных артериях: новые возможности стратификации риска развития сердечно-сосудистых осложнений у пациентов с аутоиммунными заболеваниями , 2009 .

[35]  Евгений Львович Насонов,et al.  Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите , 2009 .

[36]  L. Alfredsson,et al.  Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. , 2009, Arthritis and rheumatism.

[37]  S. Gabriel.  Why do people with rheumatoid arthritis still die prematurely? , 2008, Annals of the rheumatic diseases.

[38]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[39]  C. Weyand,et al.  The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis , 1992, Annals of Internal Medicine.